drugset
drugset / Trial / NCT07554365

A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants

NCT07554365 ↗

Phase 1 Recruiting 24 enrolled AirNexis Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

AN01 is a selective small-molecule dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4). As a potential new therapy for COPD, AN01 is expected to serve either as a monotherapy for COPD or as adjunctive therapy to current inhaled standard treatments, potentially generating synergistic complementary effects in patients requiring additional therapeutic options. The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of AN01 in healthy participants.

Timeline

Start
2026-05-13
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AN01 Small molecule — Inhaled

Indications

No indication recorded.